Increased expression of Fibrinogen-Like Protein 2 is associated with poor prognosis in patients with clear cell renal cell carcinoma.

Renal cell carcinoma. Lancet (2009) 6.92

An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol (2002) 4.59

Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol (2011) 2.10

Basic principles of real-time quantitative PCR. Expert Rev Mol Diagn (2005) 1.92

Tissue factor, thrombin, and cancer. Chest (2003) 1.81

Kidney cancer: identification of novel targets for therapy. Kidney Int (2006) 1.75

CD39 and control of cellular immune responses. Purinergic Signal (2007) 1.68

The cell-membrane prothrombinase, fibrinogen-like protein 2, promotes angiogenesis and tumor development. Thromb Res (2014) 1.39

Independent validation of the 2010 American Joint Committee on Cancer TNM classification for renal cell carcinoma: results from a large, single institution cohort. J Urol (2011) 1.36

The MAPK pathway across different malignancies: a new perspective. Cancer (2014) 1.22

Soluble fibrinogen-like protein 2/fibroleukin exhibits immunosuppressive properties: suppressing T cell proliferation and inhibiting maturation of bone marrow-derived dendritic cells. J Immunol (2003) 1.20

Prognostic value of diametrically polarized tumor-associated macrophages in renal cell carcinoma. Ann Surg Oncol (2014) 1.18

Molecular and functional analysis of the human prothrombinase gene (HFGL2) and its role in viral hepatitis. Am J Pathol (2000) 1.13

The novel CD4+CD25+ regulatory T cell effector molecule fibrinogen-like protein 2 contributes to the outcome of murine fulminant viral hepatitis. Hepatology (2009) 1.01

Role of fibrinogen-like protein 2 prothrombinase/fibroleukin in experimental and human allograft rejection. J Immunol (2005) 0.93

Increased preoperative levels of plasma fibrinogen and D dimer in patients with renal cell carcinoma is associated with poor survival and adverse tumor characteristics. Urol Oncol (2014) 0.88

Hypercoagulability as a prognostic factor for survival in patients with metastatic renal cell carcinoma. J Exp Clin Cancer Res (2009) 0.88

The novel immunoregulatory molecule FGL2: a potential biomarker for severity of chronic hepatitis C virus infection. J Hepatol (2010) 0.88

Downregulation of FGL2/prothrombinase delays HCCLM6 xenograft tumour growth and decreases tumour angiogenesis. Liver Int (2012) 0.87

FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas. J Natl Cancer Inst (2015) 0.86

Fibrinogen-like protein 2/fibroleukin prothrombinase contributes to tumor hypercoagulability via IL-2 and IFN-gamma. World J Gastroenterol (2008) 0.86

Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB signaling. Oncogene (2016) 0.84

The Role of FGL2 in the Pathogenesis and Treatment of Hepatitis C Virus Infection. Rambam Maimonides Med J (2010) 0.83

Tissue factor signal transduction in angiogenesis. Carcinogenesis (2003) 0.82

The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications. Int Rev Immunol (2014) 0.80

Fibrinogen-like protein 2 gene silencing inhibits cardiomyocytes apoptosis, improves heart function of streptozotocin-induced diabetes rats and the molecular mechanism involved. Biosci Rep (2015) 0.78

MicroRNA-497 suppress renal cell carcinoma by targeting VEGFR-2 in ACHN cells. Biosci Rep (2017) 0.77

Fibrinogen-like protein 2 expression correlates with microthrombosis in rats with type 2 diabetic nephropathy. J Biomed Res (2011) 0.77

Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond. Am J Clin Dermatol (2017) 0.77

Adenovirus-mediated artificial microRNA against human fibrinogen like protein 2 inhibits hepatocellular carcinoma growth. J Gene Med (2016) 0.77

Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells. Clin Transl Oncol (2015) 0.77

PGRMC1 Is a Novel Potential Tumor Biomarker of Human Renal Cell Carcinoma Based on Quantitative Proteomic and Integrative Biological Assessments. PLoS One (2017) 0.75

Increased activity of cell membrane-associated prothrombinase, fibrinogen-like protein 2, in peripheral blood mononuclear cells of B-cell lymphoma patients. PLoS One (2014) 0.75

Use of etanercept to treat rheumatoid arthritis in an HIV-positive patient: a case-based review. Rheumatol Int (2017) 0.75